<SEC-DOCUMENT>0000905148-25-000661.txt : 20250214
<SEC-HEADER>0000905148-25-000661.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214163304
ACCESSION NUMBER:		0000905148-25-000661
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TScan Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001783328
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				825282075
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92700
		FILM NUMBER:		25629819

	BUSINESS ADDRESS:	
		STREET 1:		880 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		857-399-9500

	MAIL ADDRESS:	
		STREET 1:		880 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			K2 HealthVentures Equity Trust LLC
		CENTRAL INDEX KEY:			0001948604
		ORGANIZATION NAME:           	
		IRS NUMBER:				842128131
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		855 BOYLSTON STREET
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		857-201-5983

	MAIL ADDRESS:	
		STREET 1:		855 BOYLSTON STREET
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001140361-22-035533</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001948604</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>3</amendmentNo>
<securitiesClassTitle>Voting Common Stock, $0.0001 par value per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001783328</issuerCik>
<issuerName>TScan Therapeutics, Inc.</issuerName>
<issuerCusip>89854M101</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>830 Winter Street</com:street1>
<com:city>Waltham</com:city>
<com:stateOrCountry>MA</com:stateOrCountry>
<com:zipCode>02451</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>K2 HealthVentures Equity Trust LLC</reportingPersonName>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>3602700</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>3602700</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3602700</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>6.9</classPercent>
<typeOfReportingPerson>OO</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Parag Shah</reportingPersonName>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>3602700</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>3602700</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3602700</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>6.9</classPercent>
<typeOfReportingPerson>IN</typeOfReportingPerson>
<typeOfReportingPerson>HC</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Anup Arora</reportingPersonName>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>3602700</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>3602700</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3602700</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>6.9</classPercent>
<typeOfReportingPerson>IN</typeOfReportingPerson>
<typeOfReportingPerson>HC</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>TScan Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>830 Winter Street, Waltham, Massachusetts, 02451</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):&#13;
&#13;
	i.     K2 HealthVentures Equity Trust LLC ("K2HV Equity");&#13;
	ii.    Parag Shah ("Mr. Shah"); and&#13;
	iii.   Anup Arora ("Mr. Arora").&#13;
&#13;
K2HV Equity is an investment vehicle for holding equity securities and may be deemed to directly beneficially own the shares of Common Stock that it holds directly.  Mr. Shah and Mr. Arora serve as the managing members of K2HV Equity and, in such capacities, may be deemed to indirectly beneficially own the shares of Common Stock that K2HV Equity holds directly.</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>The business address of each of the Reporting Persons is: 855 Boylston Street, 10th Floor, Boston, MA 02116.</principalBusinessOfficeOrResidenceAddress>
<citizenship>K2HV Equity is a Delaware limited liability company.  Each of Mr. Shah and Mr. Arora is a citizen of the United States of America.</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>As of December 31, 2024, each of the Reporting Persons may be deemed the beneficial owner of 3,602,700 shares of Common Stock, which represents approximately 6.9% of the shares of Common Stock outstanding.  &#13;
&#13;
The percentage set forth herein is calculated based on 49,094,006 shares outstanding as of November 7, 2024, as reported in the Issuer's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "Commission") on November 12, 2024, plus 3,134,796 shares of Common Stock issued to K2HV Equity on November 20, 2024, as a result of the conversion of $15 million principal amount of the term loans under the Loan and Security Agreement, dated as of September 9, 2022, between the Issuer and K2HV Equity, as reported in the Issuer's propsectus supplement on Form 424B5, filed with the Commission on December 26, 2024.</amountBeneficiallyOwned>
<classPercent>6.9</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>0</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>3,602,700</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>3,602,700</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<exhibitInfo>Exhibit 1: Joint Filing Agreement</exhibitInfo>
<signatureInformation>
<reportingPersonName>K2 HealthVentures Equity Trust LLC</reportingPersonName>
<signatureDetails>
<signature>/s/ Anup Arora</signature>
<title>Anup Arora, Managing Member</title>
<date>02/14/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Parag Shah</reportingPersonName>
<signatureDetails>
<signature>/s/ Parag Shah</signature>
<title>Parag Shah</title>
<date>02/14/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Anup Arora</reportingPersonName>
<signatureDetails>
<signature>/s/ Anup Arora</signature>
<title>Anup Arora</title>
<date>02/14/2025</date>
</signatureDetails>
</signatureInformation>
</formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>jfa.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Sidley Austin LLP
         Document created using Broadridge PROfile 25.1.1.5279
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-weight: bold;">EXHIBIT 1</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">JOINT FILING AGREEMENT</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The undersigned hereby agree that the statement on Schedule
        13G with respect to the Voting Common Stock of TScan Therapeutics, Inc., dated as of February 14, 2025, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each
      of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z336c9a71c4ab4eef917194ccbceef1ca" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>Dated: February 14, 2025</div>
          </td>
          <td style="width: 50.64%; vertical-align: top;" colspan="2">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.64%; vertical-align: top;" colspan="2">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.64%; vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">K2 HEALTHVENTURES EQUITY TRUST LLC</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 44.37%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td nowrap="nowrap" style="width: 44.37%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div>/s/ Anup Arora</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td style="width: 44.37%; vertical-align: top;">
            <div>Anup Arora</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td style="width: 44.37%; vertical-align: top;">
            <div>Managing Member</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.64%; vertical-align: top;" colspan="2">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.64%; vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">PARAG SHAH</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.64%; vertical-align: top;" colspan="2">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td style="width: 44.37%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div>/s/ Parag Shah</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.64%; vertical-align: top;" colspan="2">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.64%; vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">ANUP ARORA</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td style="width: 44.37%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div>/s/ Anup Arora</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="margin-top: 10pt;"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
